ICU SEASTAR MEDICAL HOLDING CORPORATION

SeaStar Medical to Present at Noble Capital Markets’ NobleCon20 on December 4, 2024

SeaStar Medical to Present at Noble Capital Markets’ NobleCon20 on December 4, 2024

DENVER, Nov. 26, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will present a company overview at , ’ 20th Annual Emerging Growth Equity Conference, on Wednesday, December 4 at 12:00 p.m. Eastern time (9:00 a.m. Pacific time). The conference is being held in Boca Raton, Fla.

A webcast of the presentation will be available beginning December 5 on the Company and will be archived for 90 days.

About SeaStar Medical

SeaStar Medical is a commercial-stage medical technology company that is redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical’s novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit or visit us on or .

Contact:

Alliance Advisors IR

Jody Cain

(310) 691-7100

# # #



EN
26/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SEASTAR MEDICAL HOLDING CORPORATION

 PRESS RELEASE

SeaStar Medical to Participate in the HC Wainwright 27th Annual Global...

SeaStar Medical to Participate in the HC Wainwright 27th Annual Global Investment Conference DENVER, Sept. 04, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today its participation in the upcoming HC Wainwright 27th Annual Global Investment Conference. The SeaStar Medical presentation can be viewed on Friday, September 5, 2025, at 7:00 am Eastern Time. The presentation can be accessed by visiting the ...

 PRESS RELEASE

SeaStar Medical Announces Newly Published QUELIMMUNE Health Economic S...

SeaStar Medical Announces Newly Published QUELIMMUNE Health Economic Study Projecting Significantly Reduced Health Care Costs in the Treatment of Pediatric AKI due to Estimated Shorter Hospital Stays and Increased Survival Study shows approximately 18% savings per hospitalization DENVER, Sept. 02, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today the publication of a health economic analysis estimat...

 PRESS RELEASE

SeaStar Medical Reports Second Quarter 2025 Financial Results and Prov...

SeaStar Medical Reports Second Quarter 2025 Financial Results and Provides Business Updates Business highlights include: Adult NEUTRALIZE-AKI trial enrolls 31 new patients, now over 60% enrolledThree new top-rated children’s hospitals adopt QUELIMMUNE therapy for ultra-rare pediatric Acute Kidney Injury (AKI)Positive survival results reported from QUELIMMUNE SAVE Surveillance RegistryWebcast call today at 4:30 p.m. Eastern Time DENVER, Aug. 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatm...

 PRESS RELEASE

SeaStar Medical to Report Second Quarter Financial Results on August 1...

SeaStar Medical to Report Second Quarter Financial Results on August 13, 2025 DENVER, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first quarter financial results after market close on Wednesday, August 13, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, August 13, 2025, at 4:30 p.m...

 PRESS RELEASE

SeaStar Medical Announces $4.4 Million Registered Direct Offering Pric...

SeaStar Medical Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules DENVER, July 31, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, today announced it has entered into a definitive agreement for the issuance and sale of an aggregate of 4,960,544 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.887 per share of common stock (or...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch